SCHEMBL3563537

SCHEMBL3563537

CCOc1cc(-c2cc(C(F)(F)F)nc(C(=O)O)n2)ccc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.46
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
MAPK1 P28482 5/20 0.42
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CTSS P25774 4/20 0.41
CTSK P43235 3/20 0.41
TP53 P04637 4/20 0.41
HPGD P15428 4/20 0.41
KMT2A Q03164 4/20 0.41
NPSR1 Q6W5P4 4/20 0.41
HSD17B10 Q99714 4/20 0.41
MAPT P10636 3/20 0.41
TLR9 Q9NR96 3/20 0.41
BCL2A1 Q16548 2/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561630 0.81 CTSS (0.44) MAPK1ALDH1A1CTSSCTSKTP53
SCHEMBL3562036 0.81 CTSS (0.47) ALDH1A1CTSSCTSKTP53HPGD
SCHEMBL3561409 0.81 KMO (0.49) KMOHPGDKMT2ARAB9ALMNA
SCHEMBL3565433 0.78 CTSS (0.63) CTSSCTSK
SCHEMBL3563485 0.76 SMN1; SMN2 (0.45) ALDH1A1CTSSCTSKTP53HPGD
SCHEMBL3559503 0.76 CTSS (0.40) ALDH1A1CTSSCTSKTP53HPGD
SCHEMBL4657826 0.74 CTSS (0.41) ALDH1A1CTSSCTSKTP53HPGD
SCHEMBL312526 0.74 KDM4E (0.70) MAPK1ALDH1A1L3MBTL1HPGDKMT2A
SCHEMBL3560523 0.73 ADORA3 (0.50) KMOMAPK1ALDH1A1TP53HPGD
SCHEMBL3572434 0.73 S1PR1 (0.39) ALDH1A1CTSSCTSKTP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KMO 1041/4885RXRA 710/4885RXRB 372/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KMO 1352/4885RXRA 382/4885RXRB 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.